Correction to: Cell Death Discovery 7:137; https://doi.org/10.1038/s41420-021-00496-y; published online 10 June 2021
The original version of this article unfortunately contained a mistake in the funding section. This research was funded by a Ph.D. studentship from the Royal Thai Government. Additional funding was provided by Cyclacel Ltd. This study was supported by the Glasgow Experimental Cancer Medicine Center, which is funded by Cancer Research UK [C58789/A251741] and the Chief Scientist’s Office, Scotland. Cell-sorting facilities were funded by the Kay Kendall Leukemia Fund (KKL501) and the Howat Foundation. The authors apologize for the mistake. The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Chantkran, W., Hsieh, YC., Zheleva, D. et al. Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML. Cell Death Discov. 7, 171 (2021). https://doi.org/10.1038/s41420-021-00558-1
Published:
Version of record:
DOI: https://doi.org/10.1038/s41420-021-00558-1
